Platinum Compounds for High‐Resolution In Vivo Cancer Imaging
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Platinum(II) compounds, principally cisplatin and carboplatin, are commonly used front‐line cancer therapeutics. Despite their widespread use and continued interest in the development of new derivatives, including nanoformulations with improved properties, it has been difficult to visualize platinum compounds in live subjects, in real time, and with subcellular resolution. Here, we present four novel cisplatin‐ and carboplatin‐derived fluorescent imaging compounds for quantitative intravital cancer imaging. We conjugated 4,4‐difluoro‐5,7‐dimethyl‐4‐bora‐3a,4a‐daiza‐s‐indacene (BODIPY) to Pt II complexes to generate derivatives with robust in vivo fluorescence and retained DNA‐damaging and cytotoxic properties. We successfully applied these compounds to image pharmacokinetics and tumor uptake in a xenograft cancer mouse model. By using a genetic reporter of single‐cell DNA damage for in vivo imaging, Pt drug accumulation and resultant DNA damage could be monitored in individual tumor cells, at subcellular resolution, and in real time in a live animal model of cancer. These derivatives represent promising imaging tools that will be useful in understanding further the distribution and interactions of platinum within tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Pittet, M. J., & Weissleder, R. (2011) · Cell · doi:10.1016/j.cell.2011.11.004 · Cited by 466
Self-citation
Cited by
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Self-citationCisplatin is retained in the cochlea indefinitely following chemotherapy
Breglio, A. M., Rusheen, A. E., Shide, E. D., Fernandez, K. A., Spielbauer, K. K., McLachlin, K. M., Hall, M. D., Amable, L., & Cunningham, L. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01837-1 · Cited by 412
Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347
Self-citationTeo, R. D., Hwang, J. Y., Termini, J., Gross, Z., & Gray, H. B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00400 · Cited by 289
Nano-palladium is a cellular catalyst for in vivo chemistry
Miller, M. A., Askevold, B., Mikula, H., Kohler, R. H., Pirovich, D., & Weissleder, R. (2017) · Nature Communications · doi:10.1038/ncomms15906 · Cited by 288
Self-citation
Metadata
- Authors
- Miller, M. A., Askevold, B., Yang, K. S., Kohler, R. H., & Weissleder, R.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2014-02-06
- Volume
- 9
- Issue
- 6
- Pages
- 1131-1135
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2040707183
- Cited by
- 56
- References
- 2
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.